Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 18,754 | 16,868 | 14,256 | 14,503 | 17,565 |
| Gross Profit | 18,754 | 16,868 | 14,256 | 14,503 | 17,565 |
| Operating Expenses | 27,954 | 27,705 | 29,961 | 25,710 | 23,805 |
| Operating Income | -9,200 | -10,837 | -15,705 | -11,207 | -6,240 |
| Interest Expense | 643 | 630 | 644 | 629 | 623 |
| Other Income | 904 | 1,415 | 1,128 | 1,434 | 1,847 |
| Pre-tax Income | -8,939 | -10,052 | -15,221 | -10,402 | -5,016 |
| Income Tax | 6,588 | 2,646 | 1,308 | 1,262 | 3,494 |
| Net Income Continuous | -15,527 | -12,698 | -16,529 | -11,664 | -8,510 |
| Net Income | $-15,527 | $-12,698 | $-16,529 | $-11,664 | $-8,510 |
| EPS Basic Total Ops | -0.31 | -0.26 | -0.34 | -0.24 | -0.20 |
| EPS Basic Continuous Ops | -0.32 | -0.26 | -0.34 | -0.24 | -0.20 |
| EPS Diluted Total Ops | -0.31 | -0.26 | -0.34 | -0.24 | -0.20 |
| EPS Diluted Continuous Ops | -0.32 | -0.26 | -0.34 | -0.24 | -0.20 |
| EPS Diluted Before Non-Recurring Items | -0.31 | -0.26 | -0.34 | N/A | N/A |
| EBITDA(a) | $-9,558 | $-11,204 | $-15,857 | $-11,129 | $-6,251 |